💊 Get Accurate, Objective, and Timely Intelligence From DrugPatentWatch
Profile for Incyte Corporation (INCY)
« Back to company indexINCY Chatter Timeline
Stock Ticker for INCY
Most Active Tweeters for INCY
| User | Tweets |
|---|---|
| @Tickeron | 6 |
| @optioncharts | 5 |
| @TradingChromat1 | 4 |
| @stock_titan | 3 |
| @FastestAlert | 3 |
Recent Tweets for INCY
 |
@TradingChromat1 $INCY Awaiting Short Signal. Learn more at https://t.co/emZsi1kAMx https://t.co/P2xDBCsLfj May 28th 2022, 8:05pm |
 |
@optioncharts $INCY Max Pain is 75.00 for maturity 06/17/2022. #maxpain #options https://t.co/YNyzDxPSBD https://t.co/TrrQimPPLF May 28th 2022, 5:05pm |
|
@optioncharts $INCY high OI range is 50.00 to 80.00 for option expiration 06/17/2022 PutCallRatio=0.99 #maxpain #options… https://t.co/HeEzrXNxSO May 27th 2022, 5:05pm |
|
@TradingChromat1 $INCY Awaiting Short Signal. Learn more at https://t.co/emZsi1kAMx https://t.co/AsvClicPSn May 27th 2022, 4:05pm |
 |
@ShortAlgoKing $INCY Awaiting Short Signal ? Stock Trading Ideas by https://t.co/qchl9O5K2n https://t.co/qMHLLbZAbH May 27th 2022, 11:05am |
 |
@1stOncology Data from #Incytes Robust and Progressing #Oncology Portfolio to be Presented at #EHA22 Annual Meeting $INCY https://t.co/bcF14L4hKD May 27th 2022, 8:05am |
 |
@MarcJacksonLA $INCY Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting - https://t.co/FQRY1gjDmD May 26th 2022, 8:05pm |
 |
@Tickeron $INCY in Uptrend: RSI indicator exits oversold zone. View odds for this and other indicators:… https://t.co/iWOibV6F2V May 26th 2022, 5:05pm |
 |
@LeeSinTrade1 $INCY Stock Trading Ideas | Awaiting Buy Signal. >> Learn more at https://t.co/z9Zossz5Nf https://t.co/FZxAMq9dxP May 26th 2022, 3:05pm |
|
@TradingChromat1 $INCY Awaiting Short Signal. Learn more at https://t.co/emZsi1kAMx https://t.co/5vv9q2xdUo May 26th 2022, 3:05pm |
|
@Tickeron $INCY enters bullish trend #Incyte #stockmarket #stock https://t.co/AVT9tdtUIP May 26th 2022, 2:05pm |
 |
@JanetWa28178453 $INCY Don't miss the next move in a few hours.. https://t.co/MKGf5q327P May 26th 2022, 2:05pm |
|
@Tickeron $INCY in Uptrend: price may ascend as a result of having broken its lower Bollinger Band on April 26, 2022. View od… https://t.co/K0xqfhOIHf May 26th 2022, 1:05pm |
 |
@MaiteMerenda $INCY Awaiting Buy Signal ? Stock Trading Ideas by https://t.co/t5kOjgsWN3 https://t.co/RJRNkzLW4g May 26th 2022, 12:05pm |
 |
@Gambiste1 RT @stock_titan: $INCY Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting https://t.co… May 26th 2022, 10:05am |
 |
@newsfilterio Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting $INCY https://t.co/egcIHN18XA May 26th 2022, 10:05am |
 |
@FlashAlert_me $INCY [15s. delayed]: Issued Press Release on May 26, 06:00:00: Data from Incyte’s Robust and Progressing Oncology… https://t.co/Atkuuyaj6s May 26th 2022, 10:05am |
 |
@otcdynamics $INCY Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting https://t.co/WQA7jBhc73 May 26th 2022, 10:05am |
 |
@bot_chatty RT @FastestAlert: $INCY Data From Incyte’s Robust And Progressing Oncology Portfolio To Be Presented At 2022 EHA Annual Meeting Stock News… May 26th 2022, 10:05am |
 |
@StockNewsBot2 $INCY Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting https://t.co/EdtCMoHECB May 26th 2022, 10:05am |
 |
@FastestAlert $INCY Data From Incyte’s Robust And Progressing Oncology Portfolio To Be Presented At 2022 EHA Annual Meeting Stock News Alerts In Bio May 26th 2022, 10:05am |
 |
@stock_titan $INCY Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting https://t.co/jjueTARn0X May 26th 2022, 10:05am |
 |
@UsMarketNews $INCY news Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting May 26th 2022, 10:05am |
|
@JanetWa28178453 $INCY Don't miss the next move in a few hours. https://t.co/MKGf5q327P May 26th 2022, 4:05am |
|
@TradingChromat1 $INCY Awaiting Buy Signal. Learn more at https://t.co/emZsi1kAMx https://t.co/quTbUmzTzd May 25th 2022, 4:05pm |
 |
@Biomaven @JD4for4 @drug_smolecules I’ve been told they don’t have freedom to operate until the $incy composition of matter p… https://t.co/XOJvL4EneX May 25th 2022, 1:05pm |
|
@1stOncology #Incyte to Present at Upcoming #InvestorConference $INCY https://t.co/5mtTZ6k4PQ May 25th 2022, 9:05am |
|
@Tickeron This is amazing! What do you think? $INCY MACD Histogram turned positive on May 23, 2022. #Incyte #stockmarket… https://t.co/2qnhMFbEjx May 25th 2022, 3:05am |
|
@newsfilterio Incyte to Present at Upcoming Investor Conference $INCY https://t.co/H2N0rBScNM May 25th 2022, 12:05am |
|
@Gambiste1 RT @jq1234t: @Biomaven Don’t think $INCY can develop oral ruxolitinib or follow-on compounds for AA because it licensed baricitinib and cer… May 24th 2022, 12:05pm |
 |
@jq1234t @Biomaven Don’t think $INCY can develop oral ruxolitinib or follow-on compounds for AA because it licensed bariciti… https://t.co/DAUZ9pNAEX May 24th 2022, 12:05pm |
|
@Biomaven $INCY buying them would also resolve the pricing issue for Jakafi - well over $100k a year might be OK for a cancer… https://t.co/b0p2PJjc73 May 24th 2022, 12:05pm |
|
@otcdynamics $INCY Incyte to Present at Upcoming Investor Conference https://t.co/ab2ppMkrRU May 24th 2022, 12:05pm |
|
@FlashAlert_me $INCY [15s. delayed]: Issued Press Release on May 24, 08:00:00: Incyte to Present at Upcoming Investor Conference https://t.co/g4NL8AV8mG May 24th 2022, 12:05pm |
|
@StockNewsBot2 $INCY Incyte to Present at Upcoming Investor Conference https://t.co/xklkskwOmT May 24th 2022, 12:05pm |
 |
@WebChronicleTo1 $INCY Incyte to Present at Upcoming Investor Conference https://t.co/txci11HXCR May 24th 2022, 12:05pm |
|
@FastestAlert $INCY Incyte To Present At Upcoming Investor Conference Stock News Alerts In Bio May 24th 2022, 12:05pm |
|
@stock_titan $INCY Incyte to Present at Upcoming Investor Conference https://t.co/m7KwmyyKP0 May 24th 2022, 12:05pm |
 |
@bthefirsttoknow First out// $INCY: Incyte to Present at Upcoming Investor Conference https://t.co/jNgzB4BNLp May 24th 2022, 12:05pm |
 |
@Stock_Prophecy $INCY Incyte Corporation: Reference Price 64.96, 1 Year Prediction 73.05, Potential 12.0%, #INCY May 23rd 2022, 9:05pm |
 |
@TradeWithAlerts Nice print for $INCY Size: 137480 Price: 76.91 Amount: $10,573,586.80 Time: 1600 See more: https://t.co/upA3JTyTxv… https://t.co/7eFu69HKDa May 23rd 2022, 8:05pm |
 |
@communiststocks Incyte Corp - $INCY ? QUOTE $INCY was UP ? on Fri May 20 Closed at 74.88 USD for a 0.73% gain from previous close… https://t.co/D5uDEeZwdK May 23rd 2022, 7:05am |
|
@Tickeron $INCY in Uptrend: RSI indicator exits oversold zone. View odds for this and other indicators:… https://t.co/I8rlTaj0ce May 23rd 2022, 3:05am |
|
@optioncharts $INCY Max Pain=72.50. Maturity=06/17/2022. #maxpain #options https://t.co/YNyzDxPSBD https://t.co/EJz8939Qr2 May 21st 2022, 10:05pm |
|
@MarcJacksonLA $LLY $INCY CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-A… https://t.co/pKT8DsnoEG May 20th 2022, 7:05pm |
 |
@MarketCurrents $INCY $LLY - Lilly, Incyte's Olumiant get EMA panel nod for hair loss disorder alopecia areata https://t.co/Ni0fzqU8Zo May 20th 2022, 1:05pm |
 |
@thudderwicks $LLY, $INCY The European Commission's decision is expected in the next one to two months. May 20th 2022, 12:05pm |
|
@thudderwicks $LLY, $INCY EMA's CHMP issues positive opinion for OLUMIANT https://t.co/MXAKNEAAej May 20th 2022, 12:05pm |
|
@FlashAlert_me $INCY [15s. delayed]: Issued Press Release on May 20, 08:11:00: CHMP Recommends Approval of Lilly and Incyte's OLUM… https://t.co/Ic4dkxEZPO May 20th 2022, 12:05pm |
 |
@ZoZoStockwatch $LLY $INCY CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-A… https://t.co/H3vF6CFkzd May 20th 2022, 12:05pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2022. All rights reserved.